Fundraising Fox

Envisia Therapeutics

Morrisville, US · Founded 2013 · Delaware corporation · 3 known investors

Find your way into Envisia Therapeutics

217 people in our graph share verified history with the Envisia Therapeutics team — schools, employers, funds. One of them is your warm intro.

Steve Schlenkerunlockedknows Eric Linsley · together at The Wharton School (overlapped)
×2knows the team · via McKinsey & Company
×7knows the team · via The Wharton School
×2knows the team · via Trinity College-Hartford
Biotech

Founders & leadership

BYBen Yerxa
Ben YerxainPresident2015–2017Director at Trefoil Therapeutics
ELEric Linsley
Eric LinsleyinChief Financial Officer2015–2017Managing Partner at BioInnovation Capital

Board

EMEd Mathers
Ed MathersinBoard directorPartner at New Enterprise Associates (NEA)
SBStephen Bloch
Stephen Blochin𝕏Board directorGeneral Partner at Canaan Partners
SR
Seth RudnickinBoard directorInvestor at Canaan Partners
NF
Neal FowlerBoard director
AG
Adrienne GravesBoard director
GP
Gary PhillipsBoard director

Investors · 3

New Enterprise Associates (NEA)Menlo Park · $200K – $40Mvia Ed Mathers · board
Pappas CapitalDurham
Canaan PartnersreportedStamford · $500K – $20Mvia Stephen Bloch · board

Reported raises · per SEC filings

Form D private placements

$14.7M disclosed across 2 rounds · 2015–2016

▶$10.1MraisedMar 2016 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William YelleDirector
  • Gary PhillipsDirector
  • Ed MathersDirector
  • Adrienne GravesDirector
  • Neal FowlerDirector
  • Eric LinsleyExecutive Officer
  • Ben YerxaExecutive Officer
  • Stephen BlochDirector
Offering amount
$16.5M
Amount sold
$10.1M
Proceeds to insiders
$500K
First sale
Mar 2016
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.6MraisedOct 2015 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ed MathersDirector
  • Adrienne GravesDirector
  • Stephen BlochDirector
  • Ben YerxaExecutive Officer
  • Gary PhillipsDirector
  • Seth RudnickDirector
  • Neal FowlerDirector
  • Eric LinsleyExecutive Officer
Offering amount
$5.1M
Amount sold
$4.6M
Proceeds to insiders
$500K
First sale
Oct 2015
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Envisia Therapeutics Secures $16.5 Million In Additional Series A Financingprnewswire.com · Mar 2016Envisia Therapeutics | OIS@AAO | Ophthalmology Innovation Sourceois.net · Nov 2015Sustained-release glaucoma treatment nets $25M for Liquidia's Envisia | Fierce Pharmafiercepharma.com · Nov 2013Envisia Therapeutics Debuts with $25 Million Series A Financing - Pappas Capitalpappas-capital.com · Nov 2013

Frequently asked questions

Who are Envisia Therapeutics's investors?
Envisia Therapeutics's investors include New Enterprise Associates (NEA), Pappas Capital, Canaan Partners.
How much funding has Envisia Therapeutics raised?
Envisia Therapeutics has disclosed $14.7M raised across 2 rounds.
Where is Envisia Therapeutics headquartered?
Envisia Therapeutics is headquartered in Morrisville, US.